Lixte Biotechnology Holdings, Inc. Share Price
LIXTLixte Biotechnology Holdings, Inc. Stock Performance
Open $3.54 | Prev. Close $3.45 | Circuit Range N/A |
Day Range $3.38 - $3.54 | Year Range $0.64 - $6.14 | Volume 1,075 |
Average Traded $3.46 |
Lixte Biotechnology Holdings, Inc. Share Price Chart
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Lixte Biotechnology Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
15-Jan-26 | $3.39 | $3.42 | +1.18% |
14-Jan-26 | $3.31 | $3.38 | -1.46% |
13-Jan-26 | $3.42 | $3.43 | -2.83% |
12-Jan-26 | $3.60 | $3.53 | -3.55% |
09-Jan-26 | $3.72 | $3.66 | -2.92% |
08-Jan-26 | $3.71 | $3.77 | -4.56% |
07-Jan-26 | $3.67 | $3.95 | +9.72% |